A. Passioukov

发表

Biomarkers for malignant pleural mesothelioma: current status.

P. Baas, B. Hasan, J. Welch, 2008, Molecular diagnosis & therapy.

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.

J. Tabernero, J. Soria, L. Paz-Ares, 2014, European journal of cancer.

TuBaFrost: European virtual tumor tissue banking.

P. Riegman, A. Llombart‐Bosch, P. Therasse, 2006, Advances in experimental medicine and biology.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma

F. Feuerhake, M. McGurk, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pr5 A randomized trial of radical surgery (S) versus thoracicradiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941)

G. Giaccone, C. Legrand, T. Splinter, 2005 .

Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.

J. Abarca-Quinones, D. Shochat, V. Dubois, 2001, Cancer research.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth

P. Validire, C. Sautès-Fridman, F. Petitprez, 2019, Cancer Immunology Research.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

F. Feuerhake, M. McGurk, J. Soria, 2017 .

TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network.

M M Morente, R Mager, S Alonso, 2006, European journal of cancer.

Biomarkers for Malignant Pleural Mesothelioma

P. Baas, B. Hasan, J. Welch, 2008, Molecular Diagnosis & Therapy.

Translational Medicine Case Studies and Reports

L. Audoly, P. Ferré, A. Passioukov, 2016 .

TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe.

A. L. Bosch, P. Riegman, A. Carbone, 2006, European journal of cancer.

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy

R. Spreafico, F. Farzaneh, P. Ross, 2014, British Journal of Cancer.

TuBaFrost 6: virtual microscopy in virtual tumour banking.

M M Morente, R Mager, S Alonso, 2006, European journal of cancer.

CPI-0004Na An extracellularly tumor-activated prodrug of doxorubicin

G. Yarranton, V. Dubois, A. Trouet, 2000 .

TuBaFrost 4: access rules and incentives for a European tumour bank.

M M Morente, K Knox, W N M Dinjens, 2006, European journal of cancer.

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).

G. Giaccone, J. V. van Meerbeeck, C. Legrand, 2006, European journal of cancer.

Advances in Brief Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer : Application to Doxorubicin and Preliminary in Vitro and in Vivo Studies 1

J. Abarca-Quinones, D. Shochat, V. Dubois, 2001 .

TuBaFrost 4: Access rules and incentives for a European tumour bank 5

P. Riegman, P. Therasse, J. Oosterhuis, 2006 .

TuBaFrost 5: multifunctional central database application for a European tumor bank.

M M Morente, K Knox, W N M Dinjens, 2006, European journal of cancer.

TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview.

M M Morente, R Mager, S Alonso, 2006, European journal of cancer.